Skip to main content
. 2021 Mar 27;276:119376. doi: 10.1016/j.lfs.2021.119376

Fig. 2.

Fig. 2

COVID-19 patients exhibit high concentrations of degradation glycocalyx components. Plasma was obtained from healthy controls and COVID-19 patients and glycocalyx components measured by ELISA. (A) Human heparanase activity, (B) heparan sulfate proteoglycans, and (C) hyaluronan in plasma from healthy controls (n = 7) or COVID-19 patients (n = 20). Data are shown as mean ± SEM. Student's t-test. *p < 0.05; ns: non-significant.